Clinical Trial Update: 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) trial evaluating the PET imaging agent 89Zr-DFO-REGN3767 in patients with diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• 89Zr-DFO-REGN3767 (REGN3767 radiolabeled with Zirconium-89)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Large B-cell Lymphoma, DLBCL | EARLY_Phase 1 | Status: COMPLETED